| Date issued | Product | Safety information |
| 21/05/41 |
Olmepress (Olmesartan)
|
Restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Olmepress (Olmesartan).CLICK HERE |
| 15/04/41 |
Kyprolis® ( Carfilzomib)
|
Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation.CLICK HERE |
| 11/04/41 |
Esbriet® (Pirfenidone)
|
Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI).CLICK HERE |
| 17/03/41 |
FEGONA®
|
FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception . CLICK HERE |
| 22/02/41 |
Zofran®
|
Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron) . CLICK HERE |
| 20/01/41 |
Methotrexate "Ebewe”
|
Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE "EBEWE “ for autoimmune diseases CLICK HERE |
| 12/01/41 |
Roaccutne
|
Roaccutne (isotretinoin): An update on neuropsychiatric disorders.CLICK HERE |
| 25/12/40 |
soliqua (lixisenatide /insuline glargin) soliqua
|
(lixisenatide /insuline glargin): Important information on dosing.CLICK HERE |
| 25/12/40 |
Advaquin ( levofloxacin)
|
Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection.CLICK HERE |
| 07/12/40 |
Gilenya (fingolimod)
|
Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception.CLICK HERE |